Novartis expands in gene therapy and neuroscience with $8.7 billion acquisition

9 April 2018

Flush with cash following the $13 billion sale of its consumer health joint venture stake, Swiss pharma giant Novartis (NOVN: VX) has announced a significant acquisition to expand its gene therapy and neuroscience business.

Novartis has reached an agreement and plan of merger with AveXis (Nasdaq: AVXS) to acquire the US-based clinical stage gene therapy company AveXis for $218 per share or a total of $8.7 billion in cash. AveXis shares closed down 3.o9% at $115.91 on Friday. Novartis’s shares rose 0.75% to 78.26 Swiss francs at 10.40 am in Zurich trading.

This offer represents a premium of 88% to AveXis’ closing price on April 6, 2018, and a 72% premium to the company's 30-day volume-weighted average stock price, according to the US company. The transaction, which is expected to close mid-2018, was unanimously approved by the boards of directors of both companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK